



PROPHYLACTIC VACCINE FOR HEPATITIS C AND HEPATITIS B

#KEYWORDS

Hepatitis C and B
Prophylaxis
Chimeric protein
Tests in vivo

MARKET

Approximately 170 million people around the world, i.e., 3 % of the population, are affected by the hepatitis C virus.
3 to 4 million new cases are diagnosed annually. Currently, there is no vaccine on the market, and the therapies that make it possible today to cure 40 to 80 % of sufferers experience side effects, and their price renders them unaffordable for most people.
Worldwide sales of hepatitis C therapies were \$4.1B in 2012 with a growth rate in this market at 11%, especially in Asian countries.

TECHNOLOGY DESCRIPTION

The technology is an HCV-HBV chimeric protein containing the entire E1 and E2 sequence of hepatitis C assembled in viral particles that are easy to purify.
These particles are produced in stable CHO cells and induce high titer specific antibodies for HCV and HBV in adequate models.

COMPETITIVE ADVANTAGES

- Protects against several genotypes
- Prophylactic treatment
- Complementary to the HBV vaccination

INTELLECTUAL PROPERTY

- Patent granted in France, Japan, Taiwan, Australia, and the United States.
- Being granted in Europe
- Being examined in South Korea, Canada, and India

PARTNERSHIP

Licensing

RESEARCH TEAM

Prof. Philippe Roingeard
François Rabelais University
Tours, FRANCE

SATT GRAND CENTRE

is a French tech transfer company having exclusive rights to license out technologies coming out of universities and public research organizations in France.

CONTACT

Magali **GRANGER**
Business Developer

Tél. +33 (0)6 34 22 36 89
Mail : magali.granger@sattgc.com

8, rue Pablo PICASSO
63000 CLERMONT-FERRAND

www.sattgc.com